ABIO Share Price

Open 2.55 Change Price %
High 2.55 1 Day -0.05 -2.00
Low 2.40 1 Week -0.10 -3.92
Close 2.45 1 Month -0.10 -3.92
Volume 5049 1 Year -1.24 -33.60
52 Week High 4.35
52 Week Low 2.15
ABIO Important Levels
Resistance 2 2.59
Resistance 1 2.53
Pivot 2.47
Support 1 2.37
Support 2 2.31
NASDAQ USA Most Active Stocks
FTR 2.11 -10.59%
FTR 2.11 -10.59%
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
More..
NASDAQ USA Top Gainers Stocks
LOCM 0.09 50.00%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
BGMD 0.06 20.00%
HAUP 0.06 20.00%
IDRA 2.49 19.14%
CLNT 3.08 16.23%
CGEI 0.36 16.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
QTWW 0.08 -50.00%
VALV 0.02 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
More..

ARCA biopharma, Inc. (NASDAQ: ABIO)

ABIO Technical Analysis 4
As on 22nd Mar 2017 ABIO Share Price closed @ 2.45 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 2.84 & Sell for SHORT-TERM with Stoploss of 2.59 we also expect STOCK to react on Following IMPORTANT LEVELS.
ABIO Target for March
1st Target up-side 2.74
2nd Target up-side 2.87
3rd Target up-side 3.01
1st Target down-side 2.36
2nd Target down-side 2.23
3rd Target down-side 2.09
ABIO Other Details
Segment EQ
Market Capital 4122726.75
Sector Healthcare
Industry Biotechnology
Offical website http://www.arcabiopharma.com
ABIO Address
ABIO
11080 CirclePoint Road
Suite 140
Westminster, CO 80020
United States
Phone: 720-940-2200
ABIO Latest News
Interactive Technical Analysis Chart ARCA biopharma, Inc. ( ABIO NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on ARCA biopharma, Inc.
ABIO Business Profile
ARCA biopharma, Inc. (ARCA), incorporated in 1992, is a bio-pharmaceutical company. The Company’s principal focus is developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA’s lead product candidate is Gencaro TM (bucindolol hydrochloride), a pharmacologically beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure (HF). ARCA biopharma, Inc. is a Colorado-based biopharmaceutical company developing genetically-targeted therapies for cardiovascular diseases.The Company has collaborated with LabCorp to develop the Gencaro Test, a companion test for the genetic markers that may predict clinical response to Gencaro. ARCA’s product candidate is Gencaro (bucindolol hydrochloride), a pharmacologically beta-blocker and mild vasodilator being developed for the treatment of chronic heart failure (HF). Gencaro (bucindolol hydrochloride) is a pharmacologically beta-blocker and mild vasodilator being developed for the treatment of AF. Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2 receptors in the cardiac nervous system. The Company Address is Suite 200, 8001 Arista Place, BROOMFIELD CO 80021.